Richard van Ewijk is a biotechnology quality executive and advisor with more than 25 years of experience across biologics development, GMP manufacturing, quality leadership, CDMO oversight, and regulatory compliance.

Throughout his career, Richard has supported the development, manufacture, and global development and manufacturing partners across Europe, North America, and Asia. His experience spans quality strategy, supplier governance, regulatory inspections, technology transfer, clinical development support, and the design of phase-appropriate operating models for emerging biotechnology companies.

Richard has played a key quality leadership role in landmark transactions, including the ISB 2001 AbbVie partnership — a deal valued at USD 700M upfront and up to USD 1.2B in milestones plus royalties. He has led quality and CMC due diligence across five successful out-licensing transactions and enabled more than 40 INDs and IMPDs.

Through QULLA Partners, Richard advises leadership teams on quality, governance, and development strategies that enable efficient clinical execution while maintaining compliance, oversight, and business agility — both in an advisory capacity and hands-on where technical depth is required.